WO1996004261A1 - Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes - Google Patents
Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes Download PDFInfo
- Publication number
- WO1996004261A1 WO1996004261A1 PCT/GB1995/001323 GB9501323W WO9604261A1 WO 1996004261 A1 WO1996004261 A1 WO 1996004261A1 GB 9501323 W GB9501323 W GB 9501323W WO 9604261 A1 WO9604261 A1 WO 9604261A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- benzoxazolyl
- ethoxy
- Prior art date
Links
- 0 CN(*)CCOc1ccc(C[C@](*)C(I)=O)cc1 Chemical compound CN(*)CCOc1ccc(C[C@](*)C(I)=O)cc1 0.000 description 2
- NDQPEPQDIMKEBP-GFCCVEGCSA-N C=C([C@@H](CO1)N(C(COCC(F)(F)F)=O)C1=O)c1ccccc1 Chemical compound C=C([C@@H](CO1)N(C(COCC(F)(F)F)=O)C1=O)c1ccccc1 NDQPEPQDIMKEBP-GFCCVEGCSA-N 0.000 description 1
- NSSAPVPTNNHWTR-DGCGVQPYSA-N C[C@@H](CO1)N(C([C@H](Cc(cc2)ccc2OCCN(C)C2=NC3=CC=CCC3O2)OCCOC)=O)C1=O Chemical compound C[C@@H](CO1)N(C([C@H](Cc(cc2)ccc2OCCN(C)C2=NC3=CC=CCC3O2)OCCOC)=O)C1=O NSSAPVPTNNHWTR-DGCGVQPYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Definitions
- This invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to 5 the use of such compounds and compositions in medicine.
- a 1 represents a substituted or unsubstituted aromatic heterocyclyl group
- a 2 ' represents a benzene ring having three optional subsrituents
- R ⁇ ' and R ⁇ ' each independently represent hydrogen, alkyl or alkylcarbonyl or R ⁇ ' and R ⁇ ' together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R 2 represents an aromatic heterocyclyl group only when Y' as defined below represents a bond ;
- X' represents NR' wherein R' represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
- n' represents an integer in the range of from 2 to 6.
- the compounds of formula (A) have particularly good blood-glucose lowering activity combined with freedom from adverse haematological and cardiac effects. These compounds are therefore considered to hold potential to be of particular use in the treatment and/or prophylaxis of hyperglycaemia and to be of particular use in the treatment of Type II diabetes. These compounds are also indicated to be of potential use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia and hypertension. They are also indicated to be of use in the treatment and/or prophylaxis of cardiovascular disease, especially atherosclerosis.
- these compounds are considered to be useful for treating certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over ⁇ eating, such as obesity and anorexia bulimia.
- These compounds are also indicated to be of of potential use in the treatment and/or prophylaxis of renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
- the prophylactic action of an insulin sensitiser upon nephropathy is also indicative that an insulin sensitising agent can be expected to prevent, reverse, stabilise or retard the progression of microalbuminuria to albuminuria. This is because microalbuminuria is considered to be a predictor of future nephropathy, especially in patients with clinical evidence of pre-diabetic insulin resistance syndrome, alternatively referred to as Syndrome X.
- R° represents 2-benzoxazolyl or 2-pyridyl and R ⁇ represents CH2OCH3 or CF3.
- R° represents 2-benzoxazolyl.
- R 1 represents CH2OCH3.
- R ⁇ represents CF3
- a compound of formula (I), and the pharmaceutically acceptable salts thereof may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof.
- Suitable pharmaceutically acceptable salts include salts of carboxy groups and acid addition salts.
- Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl- ⁇ -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
- Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and, where feasible, pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphonate, ⁇ -keto glutarate and ⁇ -glycerophosphate.
- Suitable pharmaceutically acceptable solvates include hydrates.
- salts and/or solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures, for example sodium salts may be prepared by using sodium methoxide in methanol.
- the present invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable hydrate thereof, which process comprises hydrolysing a compound of formula (II):
- R° and R* are as defined in relation to formula (I) and L* represents a hydrolysable group; and thereafter, if required, preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
- a suitable hydrolysable group L* is a group of formula (a) or an epimer thereof:
- a suitable hydrolysable group L* is an Evans chiral auxiliary, for example a group of formula (b) or an epimer thereof:
- a suitable hydrolysable group L ⁇ is a Ci.g alkoxy group.
- the hydrolysis of the compound of formula (II) is carried out using conditions appropriate for hydrolysing the particular group L* chosen, for example when L* is a group of formula (a) or a C g alkoxy group, the hydrolysis is suitably carried out under acidic conditions, for example using dilute sulphuric acid, conveniently in a water/dioxan mixture, for example a 1:1 mixture, at any temperature which provides a suitable rate of formation of the required product, generally at an elevated temperature, such as in the range of from 50°C to 120°C, for example 90°C; or when I_l is a group of formula (b) the hydrolysis is generally carried out using lithium hydroperoxide in an aqueous solvent, such as aqueous tetrahydrofuran, at any temperature which provides a suitable rate of formation of the required product, generally at a reduced temperature, such as in the range of from - 10°C to 0°
- the hydrolysis may be effected under basic conditions, using for example aqueous sodium hydroxide, in an appropriate solvent such as aqueous tetrahydrofuran usually at ambient temperature.
- a compound of formula (II), wherein l is a moiety of the above defined formula (a) or (b), may be prepared from a compound of formula (HI) :
- R° and R* are as defined in relation to formula (I) and L 2 represents a leaving group; (i) for compounds of formula (II) wherein L s a moiety of the above defined formula (a), by reaction with (S)-phenylglycinol; or (ii) for compounds of formula (II) wherein L* is a moiety of the above defined formula (b), by reaction with (S)-4-benzyloxazolidin-2-one, preferably an activated form thereof; and thereafter separating the required isomer from the mixture of diastereoisomers produced.
- a suitable leaving group L 2 is a halogen atom, for example a chlorine atom.
- the reaction between the compounds of formula (HI) and (S)-phenylglycinol may be carried out under conventional amidation conditions, for example in an inert solvent such as dichloromethane at a temperature which provides a suitable rate of formation of the required product, suitably at ambient temperature and preferably in the presence of a base such as rriethylamine.
- a suitable activated form of 5 -4-benzyloxazolidin-2-one is a salted form, for example an alkali metal salted form, preferably a lithium salt.
- the activated form of S -4-benzyloxazolidin-2-one may be prepared by any appropiate conventional method.
- the activated form is a lithium salt
- it may be prepared by treating S)-4-benzyloxazolidin-2-one with a source of lithium ions in the presence of a base, suitably provided by n-butyllithium, in an aprotic solvent such as tetrahydrofuran, usually at a low temperature, for example in the range of from -78° to 0°C.
- reaction between the compound of formula (III) and the activated form of ('S / )-4-benzyloxazolidin-2-one may be carried out in an aprotic solvent, such as tetrahydrofuran, at a temperature which provides a suitable rate of formation of the required product, conveniently by allowing the reaction mixture to slowly warm from -78° to 0°C.
- an aprotic solvent such as tetrahydrofuran
- the activated form of S -4-benxyloxazolidin-2-one is prepared and then reacted in-situ with the compound of formula (1 ⁇ ).
- a compound of formula (IH) may be prepared by hydrolysing the carboxylic ester COOR 2 of a compound of formula (IV):
- R° and R* are as defined in relation to formula (I) and R 2 represents an alkyl group, and thereafter converting the carboxylic acid group so formed into a moiety CO.L 2 .
- a suitable alkyl group R 2 is a Ci .5 alkyl group, especially a methyl group.
- the hydrolysis of the carboxylic ester may be effected by use of any conventional hydrolysing agent, such as an alkaline metal hydroxide, for example sodium hydroxide.
- the hydrolysis of the compound of formula (IV) may be carried out in any suitable solvent such as a methanol/water mixture, conveniently a 1 : 1 mixture, at a temperature which provides a suitable rate of formation of the required product, suitably at an elevated temperature and conveniently at the reflux temperature of the solvent.
- a suitable solvent such as a methanol/water mixture, conveniently a 1 : 1 mixture
- the conversion of the carboxylic acid group into the moiety CO.L 2 may be carried out using any appropiate conventional procedure, depending upon the particular nature of the group L 2 chosen, thus when L 2 is a halogen a suitable procedure involves treatment of the carboxylic acid with an oxalyl halide, for example oxalyl chloride when L 2 is chlorine.
- reaction conditions for the conversion of the carboxylic acid group into the moiety CO.L 2 will be dictated by the particular nature of L 2 and the source of L 2 chosen, for example when L 2 is halogen and the source of L 2 is oxalyl chloride then the reaction may be carried out in an inert solvent such as dichloromethane or benzene at a temperature which provides a suitable rate of formation of the required product, suitably at ambient temperature or at an elevated temperature such as the reflux temperature of the solvent.
- an inert solvent such as dichloromethane or benzene
- a compound of formula (II) wherein L* is a moiety of formula (b) may also be prepared by dehydroxylation of a compound of formula (V):
- the dehydroxylation of the compound of formula (V) is conveniently carried out by treatment with a trialkylsilane, for example triethylsilane, preferably in the presence of trifluoroacetic acid and conveniently using trifluoroacetic acid as solvent, at any temperature providing a suitable rate of formulation of the product, for example at a temperature in the range from 0°C to room temperature.
- a trialkylsilane for example triethylsilane
- a compound of formula (V) may be prepared by reacting a compound of formula (VIA): wherein R° is as defined in relation to formula (I), with a compound of formula (VLB):
- R ⁇ is as defined in relation to formula (I); and thereafter separating the required isomer from die mixture of diastereoisomers produced.
- the compound of formula (VLB) is in an activated form, which is preferably provided by treating the compound of formula (VIB) with an alkylboron triflate, for example dibutylboron triflate, preferably in the presence of an amine base such as triethylamine.
- the activated form of the compound of formula (VLB) may be prepared by the appropriate conventional method depending upon the specific nature of the activated form chosen, for example the compound of formula (VIB) is reacted with dibutylboron triflate and triethylamine in an inert solvent such as dichloromethane at a temperature in the range of from -78° to 0°C.
- reaction between the compounds of formulae (VIA) and (VIB) may be carried out in an in an inert solvent such as dichloromethane, at a temperature which provides a suitable rate of formation of the required product, conveniently by allowing the reaction mixture to slowly warm from -78° to 0°C.
- an inert solvent such as dichloromethane
- the activated form of the compound of formula (VIB) is prepared and then reacted in-situ with the compound of formula (VIA).
- a suitable compound of formula (VIA) is 4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]benzaldehyde.
- a suitable means for separating any required single isomer from a mixture of diastereoisomers is chromatography, such as preparative high pressure liquid chromatography or silica gel column chromatography.
- chromatography such as preparative high pressure liquid chromatography or silica gel column chromatography.
- One convenient method for preparing a compound of formula (H) wherein L* is a C ⁇ personally6 alkoxy group is the basic alcoholysis of a compound of formula (II) wherein L.1 is a moiety of formula (b).
- a suitable base is an alkali metal alkoxide, for example when L* is methoxy the compound of formula (II) wherein L* is moiety (b) is treated with sodium methoxide in methanol.
- a compound of formula (I) may also be prepared by resolving a racemic compound of formula (VII):
- R° and R 1 are as defined in relation to formula (I).
- the resolution of a compound of formula (VII) may be carried out using known resolution procedures, for example by reacting the compound of formula (VII) with a resolving agent, such as an optically active acid or base, to provide a mixture of diastereoisomeric salts which may then be separated by fractional crystallisation and thereafter the compound of formula (I) may be regenerated from the separated diastereoisomer salt by conventional means, such as hydrolysis.
- a resolving agent such as an optically active acid or base
- the compounds of formula (VII) comprise the compounds of formula (I) admixed with other optical isomers.
- a compound of formula (VH) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof forms a further aspect of the present invention.
- the separated isomers of the compounds of formula (VII), in addition to the compounds of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, also comprise the present invention.
- Suitable acids or bases for resolving the compounds of formula (VII) are as described in Enantiomers, Racemates and Resolution, J Jaques et al. 1981, Wiley Interscience, especially at pages 255 and 256. Suitable methods for effecting the resolution are also disclosed by Jaques et al.
- the compounds of formula (IV) and (VIA), for example 4-[2-[N-(2- benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde, are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in International Patent Application, Publication Number WO94/01420.
- the compounds of formula (VIB) are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in Organic Synthesis Vol. 68, p83, 1990 Ed. J.D. White or methods analogous thereto, in combination with conventional methodology for the preparation of acid chlorides.
- any reactive group in the substrate molecule may be protected, according to conventional chemical practice.
- Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art.
- the methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
- the present invention also includes a compound of formula (I) when present in admixture with less than 50% w/w of its racemic isomer, that is when it is greater than 50% optically pure, suitably 80-100% and preferably 90-100% pure, such as 90-95%, most preferably 95- 100%, for example 95%, 96%, 97%, 98%, 99% or 99.9% optically pure.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, in optically pure form in optically pure form.
- the absolute stereochemistry of compounds may be determined using conventional methods, such as X-ray crystallography.
- the present invention accordingly provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.
- the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.
- the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment and/or prophylaxis of hyperlipidaemia.
- the present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof for use in the treatment of hypertension, cardiovascular disease and certain eating disorders.
- Cardiovascular disease includes in particular atherosclerosis.
- Certain eating disorders include in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating , such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia.
- a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered pei _ or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
- the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
- composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
- compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
- compositions for oral administration are unit dosage forms such as tablets and capsules.
- Other fixed unit dosage forms, such as powders presented in sachets, may also be used.
- the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.
- Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate or sodium lauryl sulphate.
- composition will be formulated in unit dose form.
- unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 g, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.
- the present invention further provides a method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non- toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.
- the present invention further provides a med od for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.
- the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
- the compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof may be taken in doses, such as those described above, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.
- the active ingredient may be adminstered by mouth, usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemia in non-human mammals.
- the dosages regimens for the treatment of hypertension, cardiovascular disease and eating disorders will generally be those mentioned above in relation to hyperglycaemia.
- the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia.
- the present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.
- Aqueous sodium hydroxide solution (2.5M, 65 mL, 0.163 mol, 2.3 eq) was added to a stirred solution of [3(25), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]-4- benzyloxazolidin-2-one (from Procedure 10)(42.5 g, 0.071 mol) in THF (500 mL) and water (125 mL). The mixture was stirred for 20 minutes, d e reaction was diluted with water (1 L) and extracted with dichloromethane (3 x 700 mL).
- dichloromethane solutions were evaporated and the residue purified by chromatography on silica gel using 5% methanol in dichloromethane as eluent to afford 5 -4-benzyloxazolidin-2-one.
- the original aqueous solution was acidified to pH 3.5 wim dilute hydrochloric acid and re-extracted with dichloromeUiane (3 x 700 mL).
- the dichloromethane solutions from the acid extraction were dried (MgSO 4 ) and evaporated to give a solid. This was recrystallised from dichloromethane-diethyl ether to afford the title compound, mp 119.5-120.5°C.
- Oxalyl chloride (1.1 mL) was added to a solution of ( ⁇ )-3-[4-[2-[N-(2-benzoxazolyl)- N-methylamino]ethoxy]phenyl]-2-(2,2 ⁇ -trifluoroethoxy)propanoic acid (1.72 g) in dry benzene (30 mL). The mixture was heated at reflux for 2 hours, cooled and evaporated to dryness to give the title compound as a gum which was used widiout further purification.
- the resulting mixture was stirred at -78°C for 30 minutes, then warmed from -78°C to 0°C over 60 minutes along a linear gradient (warming rate ⁇ 1.3°C.min- 1 ) and stirred at 0°C for a further 75 minutes.
- the reaction mixture was poured into a quenching solution of methanol (500 mL), pH 7 phosphate buffer (250 mL) and hydrogen peroxide (27.5% w/v, 110 mL) and stirred vigourously for 30 minutes. Water (4 L) was added, the layers were separated and the aqueous layer was extracted with dichloromethane (3 x 1 L).
- Triediylsilane 120 mL, 0.75 mol was added over 5 minutes to a stirred, ice cooled solution of [3(25, 3 ⁇ ), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N- med ⁇ ylamino]ethoxy]phenyl]-3-hydroxy-2-(2 ⁇ ,2-trifluoroethoxy)propanoyl]-4- benzyloxazolidin-2-one (46.23 g, 7.5 x 10" 2 mol) in trifluoroacetic acid (650 mL). The mixture was stirred at 0°C for 1 hour, then at room temperature for a further 60 hours.
- the tide compound was prepared from (45)-4-benzyl-3-[2-(2- methoxyethoxy)ethanoyl]oxazolidin-2-one by a method analogous to that described in Procedure 9.
- the crude reaction mixture was chromatographed on silica gel using a gradient of 15-40% ethyl acetate in dichloromediane to afford die product as a gum (comprising 2 diastereoisomers, ratio >99:1 by ! H NMR).
- mice C57M1/6 obese (ob/ob) mice were fed on powdered oxoid diet. After at least one week, the mice continued on a powdered oxoid diet or were fed powered oxoid diet containing die test compound. After 8 days on the supplemented diet all of die mice were fasted for 5 hours prior to receiving an oral load of glucose (3g/kg). Blood samples for glucose analysis were taken 0, 45, 90 and 135 minutes after glucose administration and d e results appear below as the percentage reduction in area under die blood glucose curve where test compound treated groups are compared with die control group. 8 mice were used for each treatment.
Abstract
A compound of formula (I): or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein Ro represents 2-benzoxazolyl or 2-pyridyl and R1 represents CH¿2?OCH3 or CF3; a process for the preparation of such compounds, a pharmaceutical composition containing such compounds and the use of such compounds and compositions in medicine.
Description
BENZOXAZOLES AND PRYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF THE TYPE I I DIABETES
This invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to 5 the use of such compounds and compositions in medicine.
International Patent Application, Publication Number WO 94/01420 discloses compounds of formula (A):
A 1 '-X'-(CH2)n-O-A2'- A3'- Y.R2' (A)
10 or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:
A 1 represents a substituted or unsubstituted aromatic heterocyclyl group;
A2' represents a benzene ring having three optional subsrituents;
15 A3' represents a moiety of formula -(CH2)m-CH(OR^ )- wherein R1' represents substituted or unsubstituted alkyl, aryl, aralkyl or alkylcarbonyl and m represents an integer in the range of from 1 to 5, or A3' represents a moiety of formula -(CH2)m'-l- CH=C(0R1')- wherein R1' and m' are as defined above; R2' represents OR3' wherein R3' represents hydrogen, alkyl, aryl or aralkyl or R2'
20 represents an aromatic heterocyclyl group or -NR^ R^' wherein R^' and R^' each independently represent hydrogen, alkyl or alkylcarbonyl or R^' and R^' together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R2 represents an aromatic heterocyclyl group only when Y' as defined below represents a bond ;
25 X' represents NR' wherein R' represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
Y' represents C=O or C=S or a bond providing that Y' represents a bond only when R2' represents the above mentioned aromatic heterocyclyl group; and
30 n' represents an integer in the range of from 2 to 6.
These compounds are stated to have inter alia good blood-glucose lowering activity and are therefore of potential use in the treatment and/or prophylaxis of hyperglycaemia and to be of particular use in the treatment of Type II diabetes.
It has now surprisingly been discovered that a particular group of compounds
35 falling within the generic scope of the compounds of formula (A) have particularly good blood-glucose lowering activity combined with freedom from adverse haematological and cardiac effects. These compounds are therefore considered to hold potential to be of particular use in the treatment and/or prophylaxis of hyperglycaemia and to be of particular use in the treatment of Type II diabetes.
These compounds are also indicated to be of potential use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia and hypertension. They are also indicated to be of use in the treatment and/or prophylaxis of cardiovascular disease, especially atherosclerosis. In addition these compounds are considered to be useful for treating certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over¬ eating, such as obesity and anorexia bulimia.
These compounds are also indicated to be of of potential use in the treatment and/or prophylaxis of renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease. The prophylactic action of an insulin sensitiser upon nephropathy is also indicative that an insulin sensitising agent can be expected to prevent, reverse, stabilise or retard the progression of microalbuminuria to albuminuria. This is because microalbuminuria is considered to be a predictor of future nephropathy, especially in patients with clinical evidence of pre-diabetic insulin resistance syndrome, alternatively referred to as Syndrome X.
Accordingly, the present invention provides a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein R° represents 2-benzoxazolyl or 2-pyridyl and R^ represents CH2OCH3 or CF3.
Preferably, R° represents 2-benzoxazolyl.
Suitably, R1 represents CH2OCH3.
Preferably, R^ represents CF3
As indicated above, a compound of formula (I), and the pharmaceutically acceptable salts thereof, may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof.
Suitable pharmaceutically acceptable salts include salts of carboxy groups and acid addition salts. Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium
or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-β-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and, where feasible, pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphonate, α-keto glutarate and α-glycerophosphate.
Suitable pharmaceutically acceptable solvates include hydrates.
The salts and/or solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures, for example sodium salts may be prepared by using sodium methoxide in methanol.
In a further aspect the present invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable hydrate thereof, which process comprises hydrolysing a compound of formula (II):
wherein R° and R* are as defined in relation to formula (I) and L* represents a hydrolysable group; and thereafter, if required, preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
A suitable hydrolysable group L* is a group of formula (a) or an epimer thereof:
H (a)
A suitable hydrolysable group L* is an Evans chiral auxiliary, for example a group of formula (b) or an epimer thereof:
A suitable hydrolysable group L^ is a Ci.g alkoxy group. The hydrolysis of the compound of formula (II) is carried out using conditions appropriate for hydrolysing the particular group L* chosen, for example when L* is a group of formula (a) or a C g alkoxy group, the hydrolysis is suitably carried out under acidic conditions, for example using dilute sulphuric acid, conveniently in a water/dioxan mixture, for example a 1:1 mixture, at any temperature which provides a suitable rate of formation of the required product, generally at an elevated temperature, such as in the range of from 50°C to 120°C, for example 90°C; or when I_l is a group of formula (b) the hydrolysis is generally carried out using lithium hydroperoxide in an aqueous solvent, such as aqueous tetrahydrofuran, at any temperature which provides a suitable rate of formation of the required product, generally at a reduced temperature, such as in the range of from - 10°C to 0°C, for example 0°C. Alternatively, when L s a group of formula (b) the hydrolysis may be effected under basic conditions, using for example aqueous sodium hydroxide, in an appropriate solvent such as aqueous tetrahydrofuran usually at ambient temperature. A compound of formula (II), wherein l is a moiety of the above defined formula (a) or (b), may be prepared from a compound of formula (HI) :
wherein R° and R* are as defined in relation to formula (I) and L2 represents a leaving group; (i) for compounds of formula (II) wherein L s a moiety of the above defined formula (a), by reaction with (S)-phenylglycinol; or (ii) for compounds of formula (II) wherein L* is a moiety of the above defined formula (b), by reaction with (S)-4-benzyloxazolidin-2-one, preferably an activated form thereof; and thereafter separating the required isomer from the mixture of diastereoisomers produced.
A suitable leaving group L2 is a halogen atom, for example a chlorine atom.
The reaction between the compounds of formula (HI) and (S)-phenylglycinol may be carried out under conventional amidation conditions, for example in an inert solvent such as dichloromethane at a temperature which provides a suitable rate of formation of the required product, suitably at ambient temperature and preferably in the presence of a base such as rriethylamine.
A suitable activated form of 5 -4-benzyloxazolidin-2-one is a salted form, for example an alkali metal salted form, preferably a lithium salt.
The activated form of S -4-benzyloxazolidin-2-one may be prepared by any appropiate conventional method. Thus when the activated form is a lithium salt, it may be prepared by treating S)-4-benzyloxazolidin-2-one with a source of lithium ions in the presence of a base, suitably provided by n-butyllithium, in an aprotic solvent such as tetrahydrofuran, usually at a low temperature, for example in the range of from -78° to 0°C.
The reaction between the compound of formula (III) and the activated form of ('S/)-4-benzyloxazolidin-2-one may be carried out in an aprotic solvent, such as tetrahydrofuran, at a temperature which provides a suitable rate of formation of the required product, conveniently by allowing the reaction mixture to slowly warm from -78° to 0°C.
Preferably, the activated form of S -4-benxyloxazolidin-2-one is prepared and then reacted in-situ with the compound of formula (1Η).
A compound of formula (IH) may be prepared by hydrolysing the carboxylic ester COOR2 of a compound of formula (IV):
wherein R° and R* are as defined in relation to formula (I) and R2 represents an alkyl group, and thereafter converting the carboxylic acid group so formed into a moiety CO.L2.
A suitable alkyl group R2 is a Ci .5 alkyl group, especially a methyl group. The hydrolysis of the carboxylic ester may be effected by use of any conventional hydrolysing agent, such as an alkaline metal hydroxide, for example sodium hydroxide.
The hydrolysis of the compound of formula (IV) may be carried out in any suitable solvent such as a methanol/water mixture, conveniently a 1 : 1 mixture, at a temperature which provides a suitable rate of formation of the required product, suitably at an elevated temperature and conveniently at the reflux temperature of the solvent.
The conversion of the carboxylic acid group into the moiety CO.L2 may be carried out using any appropiate conventional procedure, depending upon the particular nature of the group L2 chosen, thus when L2 is a halogen a suitable procedure involves treatment of the carboxylic acid with an oxalyl halide, for example oxalyl chloride when L2 is chlorine.
The reaction conditions for the conversion of the carboxylic acid group into the moiety CO.L2 will be dictated by the particular nature of L2 and the source of L2 chosen, for example when L2 is halogen and the source of L2 is oxalyl chloride then the reaction may be carried out in an inert solvent such as dichloromethane or benzene at a temperature which provides a suitable rate of formation of the required product, suitably at ambient temperature or at an elevated temperature such as the reflux temperature of the solvent.
It will be appreciated that die preparation and separation of a compound of formula (II) wherein i is an epimer of the above defined moiety (a) or (b) and its subsequent hydrolysis to afford a compound of formula (I) can be achieved by employing analogous methods to those described above for the preparation, separation and hydrolysis of a compound of formula (II) wherein i represents the above defined moiety (a) or (b).
A compound of formula (II) wherein L* is a moiety of formula (b) may also be prepared by dehydroxylation of a compound of formula (V):
(V) wherein R° and R1 are as defined in relation to formula (I) and X is a moiety of the above defined formula (b).
The dehydroxylation of the compound of formula (V) is conveniently carried out by treatment with a trialkylsilane, for example triethylsilane, preferably in the presence of trifluoroacetic acid and conveniently using trifluoroacetic acid as solvent, at any temperature providing a suitable rate of formulation of the product, for example at a temperature in the range from 0°C to room temperature.
It will be appreciated that a compound of formula (II) wherein L is a moiety of formula (b) would also be obtained by dehydroxylation of a compound of formula
(V) in which the hydroxy bearing stereocentre is epimerised.
A compound of formula (V) may be prepared by reacting a compound of formula (VIA):
wherein R° is as defined in relation to formula (I), with a compound of formula (VLB):
wherein R^ is as defined in relation to formula (I); and thereafter separating the required isomer from die mixture of diastereoisomers produced.
Suitably in the above mentioned reaction, the compound of formula (VLB) is in an activated form, which is preferably provided by treating the compound of formula (VIB) with an alkylboron triflate, for example dibutylboron triflate, preferably in the presence of an amine base such as triethylamine. The activated form of the compound of formula (VLB) may be prepared by the appropriate conventional method depending upon the specific nature of the activated form chosen, for example the compound of formula (VIB) is reacted with dibutylboron triflate and triethylamine in an inert solvent such as dichloromethane at a temperature in the range of from -78° to 0°C. The reaction between the compounds of formulae (VIA) and (VIB) may be carried out in an in an inert solvent such as dichloromethane, at a temperature which provides a suitable rate of formation of the required product, conveniently by allowing the reaction mixture to slowly warm from -78° to 0°C.
Preferably, the activated form of the compound of formula (VIB) is prepared and then reacted in-situ with the compound of formula (VIA).
For compounds of formula (I) wherein R° represents 2-benzoxazolyl, a suitable compound of formula (VIA) is 4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]benzaldehyde.
A suitable means for separating any required single isomer from a mixture of diastereoisomers is chromatography, such as preparative high pressure liquid chromatography or silica gel column chromatography.
One convenient method for preparing a compound of formula (H) wherein L* is a C ι„6 alkoxy group is the basic alcoholysis of a compound of formula (II) wherein L.1 is a moiety of formula (b).
A suitable base is an alkali metal alkoxide, for example when L* is methoxy the compound of formula (II) wherein L* is moiety (b) is treated with sodium methoxide in methanol.
A compound of formula (I) may also be prepared by resolving a racemic compound of formula (VII):
The resolution of a compound of formula (VII) may be carried out using known resolution procedures, for example by reacting the compound of formula (VII) with a resolving agent, such as an optically active acid or base, to provide a mixture of diastereoisomeric salts which may then be separated by fractional crystallisation and thereafter the compound of formula (I) may be regenerated from the separated diastereoisomer salt by conventional means, such as hydrolysis.
It will be appreciated that the compounds of formula (VII) comprise the compounds of formula (I) admixed with other optical isomers. A compound of formula (VH) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, forms a further aspect of the present invention. The separated isomers of the compounds of formula (VII), in addition to the compounds of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, also comprise the present invention. Suitable acids or bases for resolving the compounds of formula (VII) are as described in Enantiomers, Racemates and Resolution, J Jaques et al. 1981, Wiley Interscience, especially at pages 255 and 256. Suitable methods for effecting the resolution are also disclosed by Jaques et al.
The compounds of formula (IV) and (VIA), for example 4-[2-[N-(2- benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde, are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in International Patent Application, Publication Number WO94/01420.
The compounds of formula (VIB) are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in Organic Synthesis Vol. 68, p83, 1990 Ed. J.D. White or
methods analogous thereto, in combination with conventional methodology for the preparation of acid chlorides.
It will be appreciated that in any of the abovementioned reactions any reactive group in the substrate molecule may be protected, according to conventional chemical practice. Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.
It will be appreciated that the above mentioned preparation of the compounds of formula (I), or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, is a stereoselective procedure and that the compound of formula (I) is a single stereoisomer. The present invention also includes a compound of formula (I) when present in admixture with less than 50% w/w of its racemic isomer, that is when it is greater than 50% optically pure, suitably 80-100% and preferably 90-100% pure, such as 90-95%, most preferably 95- 100%, for example 95%, 96%, 97%, 98%, 99% or 99.9% optically pure.
In one preferred aspect there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, in optically pure form. The absolute stereochemistry of compounds may be determined using conventional methods, such as X-ray crystallography.
As mentioned above the compounds of the invention are indicated as having useful therapeutic properties: The present invention accordingly provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.
Thus the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.
In a further aspect the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment and/or prophylaxis of hyperlipidaemia.
As indicated hereinbefore the present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof for use in the treatment of hypertension, cardiovascular disease and certain eating disorders.
Cardiovascular disease includes in particular atherosclerosis.
Certain eating disorders include in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating ,such as
anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia.
A compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered pei _ or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
Accordingly, the present invention also provides a pharmaceutical composition comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.
In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant. Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate or sodium lauryl sulphate.
Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 g, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.
The present invention further provides a method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non- toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.
The present invention further provides a med od for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a pharmaceutically
acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.
Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
In the treatment and/or prophylaxis of hyperglycaemic humans, and/or the treatment and/or prophylaxis of hyperlipidaemic human, the compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be taken in doses, such as those described above, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.
In the treatment and/or prophylaxis of hyperglycaemic non-human mammals, especially dogs, the active ingredient may be adminstered by mouth, usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemia in non-human mammals.
The dosages regimens for the treatment of hypertension, cardiovascular disease and eating disorders will generally be those mentioned above in relation to hyperglycaemia.
In a further aspect the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia. The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.
No toxicological effects have been established for a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in the abovementioned dosage ranges.
The following Procedures and Examples illustrate the invention but do not limit it in any way.
Example 1 5)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxy- ethoxy)propanoic acid
A solution of [2S, N(lS)]-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]- phenyl]-2-(2-methoxyethoxy)-N-(2-hydroxy-l-phenyledιyl)propanamide (1.846 g) in a mixture of 1M sulphuric acid (45 mL) and dioxan/water (1:1, 150 mL) was heated at 90°C for 56 hours and then the pH of the mixture was adjusted to pH 3 by addition of aqueous sodium hydrogen carbonate. The mixture was extracted with ethyl acetate and the organic extracts washed with water, brine, dried (MgSO4) and evaporated to give an oil. Purification by chromatography on silica gel using a gradient of 1-5% metiianol in dichloromethane as eluent gave a foam of 88% e.e. (by HPLC). The product was reacted with 5 -α-methylbenzylamine in acetone, and the resulting salt recrystallised several times from ethyl acetate-hexane before being dissolved in water, acidified with dilute hydrochloric acid and extracted with ethyl acetate which was dried with MgSO Evaporation of the ethyl acetate solution afforded enantiomerically enriched title compound; [α]D 25 -28° (c=0.625, CHCI3); e.e 94% (by HPLC); [Found M+ 414.1791. C22H26N2O6 requires M+ 414.1791]; >H NMR spectrum identical with that described in Example 5.
Example 2
(S)-3-[4-[2-[N.(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2 2,2- trifluoroethoxy)propanoic acid by hydrolysis of amide
[2S, N(lS)]-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide (from Procedure 3) was hydrolysed by an analogous procedure to that described in Example 1. Purification by chromatography on silica gel using a gradient of 0-5% methanol in dichloromethane as eluent gave the title compound, mp 116-7°C, after trituration with diethyl ether-hexane; [α]D 25 -24.6° (c=0.24, CHCI3); e.e. 95% (by HPLC). [Found C, 57.9; H, 4.7; N, 6.8%; M+ 438.1403. C21H21F3N2O5 requires C, 57.5; H,
4.8; N, 6.4%; M+ 438.1403]; δH (DMSO-dg) 2.96 (2H,m), 3.22 (3H,s), 3.88 (2H,m), 3.95-4.18 (2H,m), 4.27 (3H,m), 6.8-7.37 (8H,m) and 12.9 (lH,br s, exchanges with D2O).
Example 3 S>-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl-2-(2A2- trifluoroethoxy)propanoic Acid, by Direct Hydrolysis of the Imide
Aqueous sodium hydroxide solution (2.5M, 65 mL, 0.163 mol, 2.3 eq) was added to a stirred solution of [3(25), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]-4- benzyloxazolidin-2-one (from Procedure 10)(42.5 g, 0.071 mol) in THF (500 mL) and water (125 mL). The mixture was stirred for 20 minutes, d e reaction was diluted with water (1 L) and extracted with dichloromethane (3 x 700 mL). These dichloromethane solutions were evaporated and the residue purified by chromatography on silica gel using 5% methanol in dichloromethane as eluent to afford 5 -4-benzyloxazolidin-2-one. The original aqueous solution was acidified to pH 3.5 wim dilute hydrochloric acid and re-extracted with dichloromeUiane (3 x 700 mL). The dichloromethane solutions from the acid extraction were dried (MgSO4) and evaporated to give a solid. This was recrystallised from dichloromethane-diethyl ether to afford the title compound, mp 119.5-120.5°C. [a]D^ = -31° (c = 2.50, CHC13); e.e. 99.6% (by HPLC); [Found C, 57.7; H, 4.7; N, 6.25%; M+ (El) 438.1412. C21H21F3N2O5 requires C, 57.5; H, 4.8; N, 6.4%; M+ 438.1403]; δH (CDCI3) 3.05 (IH, dd), 3.13 (IH, dd), 3.31 (3H, s), 3.72 (IH, m), 3.89 (2H, ), 4.04- 4.14 (3H, m), 4.21 (IH, dd), 6.78 (2H, d), 7.03-7.40 (6H, m) and 11.20 (IH, br, exchanges with D2O); δp (DMSO-dg) = -72.7 (3F, t, V^p 9.3 Hz, CF3).
Example 4 5 -3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl-2-(2^,2-tri- fluoroethoxy)propanoic Acid by Hydrolysis of Methyl Ester
A mixture of (Sj-methyl 3-[4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoate (1.256 g, 2.8 x 10"3
mol), aqueous hydrochloric acid (2.0M, 50 mL) and dioxan (50 mL) was heated at reflux for 7 hours, cooled and concentrated in vacuo. The residue was suspended in brine (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined ediyl acetate solutions were dried (MgSO4) and evaporated to afford a waxy solid. This solid was triturated with hexane, filtered and dried under vacuum at 65°C to afford the desired product, mp 113-5°C. [αJo25 = -32° (c = 1.02, CHC13); e.e. 99.4% (by HPLC); [Found C, 57.25; H, 4.8; N, 6.3%. C21H21F3N2θ5 requires C, 57.5; H, 4.8; N, 6.4%]. The lU NMR spectrum of this material was identical to that produced in Example 3.
Example 5 S)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl-2-(2- methoxyethoxy)propanoic Acid
(S)-Methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoate was hydrolysed in a manner analogous to that described for Example 4. The crude reaction mixture was chromatographed on silica gel using 5% methanol in dichloromethane as eluent to afford the title compound, a gum. [α]D 25 = -27° (c = 0.73, CHCI3); e.e. 99.8% (by HPLC); [Found M+ (El) 414.1779. C22H26N2O6 requires M+ 414.1791]; δH (CDCI3) 2.90 (IH, dd), 3.15 (IH, dd), 3.33 (3H, s), 3.37 (3H, s), 3.40-3.70 (4H, m), 3.93 (2H, t), 4.05 (IH, dd), 4.21 (2H, t), 6.81 (2H, d) and 6.95-7.40 (6H,m).
Procedure 1
(±)-3-[4-[2-[N-(2-BenzoxazolyI)-N-methyiamino]ethoxy]phenyl]-2-(2- methoxyethoxy]propanoic acid
A mixture of methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2- (2-methoxyethoxy)propanoate (1.08 g, Int. Patent Appl., Publication No. WO 9401420) and sodium hydroxide (253 mg) in methanol: water (1:1, 10 mL) was heated under reflux for 2 hours. After evaporation of the resultant mixture in vacuo, the residue was diluted with water, acidified to pH 5 with 2M hydrochloric acid and then extracted widi emyl acetate. Washing of die ediyl acetate extracts witii water and drying (MgSO ) and evaporation gave the title compound as an oil which crystallised on trituration with diethyl ether/hexane. [Found C, 63.8; H, 6.5; N, 7.0%; M+ 414.1791. C22H26N2O6 requires C, 63.8; H, 6.3; N, 6.8%; M+ 414.1791]; δH (CDC13) 2.91 (lH,dd), 3.15 (lH,dd), 3.34 (3H,s), 3.38 (3H,s), 3.41-3.69 (4H,m), 3.93 (2H,t), 4.05 (lH,dd), 4.21 (2H,t), 6.80 (2H,d) and 6.83-7.38 (6H m).
Procedure 2
(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoyl chloride
Oxalyl chloride (92 mg) was added to (±)-3-[4-[2-[N-(2-benzoxazolyl)-N-methyl- amino]ethoxy]phenyl]-2-(2-methoxyethoxy)propanoic acid (100 mg) in dichloromethane (2 mL). The mixture was stirred at room temperature for 16 hours and evaporated to dryness to give die title compound as a gum which was used widiout further purification.
Procedure 3
[25, N(LS)]-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide
(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-med ylamino]emoxy]phenyl]-2-(2-methoxy- ethoxy)propanoyl chloride was dissolved in dichloromethane (2 mL) and a mixture of 5)-2-phenylglycinol (33 mg) and dry triediylamine (37 mg) in dichloromethane (1 mL) added. After stirring for 5 minutes water was added and the mixture extracted witii dichlorometiiane. The organic extracts were washed with water, brine, dried (MgSO4) and evaporated. The residue was chromatographed on silica gel using a gradient of 10-50% acetone in hexane as eluent to afford firstly [2R, N(15)]-3-[4-[2- [N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxyethoxy)-N-(2- hydroxy- l-phenyledιyl)propanamide followed by the desired [25, N(15)]- propanamide title compound as a foam. [α]r>25 -33° (c=l.l, CHCI3); 92.6% d.e. (by HPLC); [Found M+ 533.2526. CSQ^S^OS requires M+ 533.2526]; δH (CDCI3) 2.81 (lH,dd), 3.07 (lH,dd), 3.35 (3H,s), 3.36 (3H,s), 3.48-3.58 (2H,m), 3.52-3.62 (2H,m), 3.71 (lH,dd), 3.82 (lH,dd), 3.94 (lH,dd), 3.93 (2H,t), 4.22 (3H,t), 5.05 (lH,dt), 6.75-7.35 (13H,complex), 7.54 (lH,br, exchanges with D2O).
Procedure 4
(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2^,2- trifluoroethoxy)propanoic acid
Methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)propanoate (Int. Patent Appi, Publication No. WO 9401420) was hydrolysed by an analogous procedure to that described in Procedure 1 to give the title compound as a solid, mp 116-117°C; [Found C, 57.4; H, 4.9; N, 6.4%. C21H2ιF3N2O5 requires C, 57.5; H, 4.8; N, 6.4%]; δH (CDC13) 3.03-3.17 (2H,m), 3.29 (3H,s), 3.73-3.83 (lH,m), 3.85 (2H,m), 4.02 (2H,m), 4.04-4.30 (2H,m) and 6.74-7.40 (8H m).
Procedure 5
(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2Λ2- trifluoroethoxy)propanoyl chloride
Oxalyl chloride (1.1 mL) was added to a solution of (±)-3-[4-[2-[N-(2-benzoxazolyl)- N-methylamino]ethoxy]phenyl]-2-(2,2^-trifluoroethoxy)propanoic acid (1.72 g) in dry benzene (30 mL). The mixture was heated at reflux for 2 hours, cooled and evaporated to dryness to give the title compound as a gum which was used widiout further purification.
Procedure 6 [2S, N(lS)]-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifϊuoroethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide
(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)propanoyl chloride was reacted with (5 -2-phenylglycinol by an analogous procedure to that described in Procedure 3. Chromatography on silica gel using a gradient of 10-70% ethyl acetate in hexane as eluent afforded firstly [2R, N(15)]-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide followed by the desired [25, N(15)]-propanamide title compound as a foam; [α]D 25 +14° (c=0.5, MeOH); 99% d.e. (by HPLC); [Found M+ 557.2136. C^r^^Os requires M+ 557.2138]; δH (CDC13) 2.35 (lH,br, exchanges with D2O), 2.91 (lH,dd), 3.13 (lH,dd), 3.36 (3H,s), 3.70-3.87 (2H,m), 3.84 (2H,d), 3.95 (2H,t), 4.12 (lH,dd),4.22 (2H,t), 5.01 (lH,m), 6.75 (2H,d), 6.97 (lH,br s, exchanges with D2O) and 7.01-7.36 (HH,complex).
Procedure 7 (2,2,2-Trifluoroethoxy)ethanoyl Chloride
A solution of oxalyl chloride (20 mL, 0.23 mol, 1.15 eq) in dry dichloromethane (50 mL) was added dropwise at room temperature, widi stirring, to a solution of (2,2,2- trifluoroed oxy)ethanoic acid (Int. Patent Appl., Publication No. WO 87/07270, 31.6 g, 0.2 mol) and N,N-dimethylformamide (5 drops) in dry dichlorometiiane (400 mL). The mixture was stirred for an additional hour, tiien heated under reflux for 2 hours, cooled and d e bulk of d e solvent removed by distillation (bp 40-45°C 760 mm Hg). The residue was transferred to a Claisen distillation flask and the remaining solvent and oxalyl chloride removed by distillation (bp 45-60°C/760 mm Hg). Vacuum distillation of the residue then afforded the product, bp 50-55 25-32 mm Hg. δH (CDC13) 4.00 (2H, q, 3JHF 8.3) and 4.57 (2H, s).
Procedure 8 (45)-4-Benzyl-3-[2-(2,2,2-trifluoroethoxy)ethanoyl]oxazoUdin-2-one
(45)-4-Benzyloxazolidine-2-one (5.21 g, 0.029 mol) was dissolved in dry THF
(60 mL) and cooled to -70°C under argon. π-Butyllithium (18.4 mL, 1.6 M solution in hexane, 1.1 eq) was added over 10 minutes and the resulting mixture stirred at -70° C for 20 minutes. A solution of (2,2,2-trifluoroetiιoxy)ethanoyl chloride (5.19 g, 1 eq) in dry THF (60 mL) was added over 10 minutes, the mixture stirred at -70°C for a further 30 minutes then allowed to warm to room temperature overnight. The reaction was quenched by addition of brine (20 mL) and concentrated in vacuo. The residue was diluted with brine (300 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were dried (MgSO4), evaporated and the residue chromatographed on silica gel with dichloromethane as eluent to give the product as an oil. [α]D 25 = +48° (c = 2.55, CHCI3); e.e. 100% (by HPLC); [Found (CI, Ammonia) MH+ 318.0934. C14H14NO4F3 requires MH+ 318.0953]; δH (CDCI3) 2.82 (IH, dd), 3.34 (IH, dd), 4.02 (2H, q, HF 8-6), 4.30 (2H, m), 4.69 (IH, m), 4.84 (2H, s) and 7.15-7.40 (5H, m); δp (CDCI3) = -74.8 (3F, t, 3yw 8.6, CF3).
Procedure 9
[3(2S, 3R), 4S]-3-[3-[4-[2-[N.(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl].3- hydroxy-2-(2,2,2-trifluoroethoxy)propanoyl]-4-benzyloxazolidin-2-one
(45)-4-Benzyl-3-[2-(2^,2-trifluoroethoxy)ethanoyl]oxazolidin-2-one (31.7 g, 0.1 mol) was dissolved in dry dichloromethane (300 mL) under argon and cooled to - 78°C (internal temperature of solution), using liquid nitrogen/acetone as the cooling medium. Triediylamine (16.72 mL, 1.2 eq) was added, followed by the slow addition, over approximately 10 minutes, of di-π-butylboron triflate (Aldrich Chemical Company, 1.0M solution in dichloromethane, 110 mL, 1.1 eq) such that die reaction temperature was maintained below -70°C. The mixture was stirred at -78°C for 50 minutes, dien d e cooling bath was replaced with an ice batii and the mixture stirred at 0°C for an additional 50 minutes before being recooled to -78°C. A solution of 4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde (29.6 g, 1.0 eq) in dry dichloromethane (220 mL), precooled to -50°C, was added over ca. 12 minutes, such diat the reaction temperature was maintained below -70°C. The resulting mixture was stirred at -78°C for 30 minutes, then warmed from -78°C to 0°C over 60 minutes along a linear gradient (warming rate ~ 1.3°C.min-1) and stirred at 0°C for a further 75 minutes. The reaction mixture was poured into a quenching solution of methanol (500 mL), pH 7 phosphate buffer (250 mL) and hydrogen peroxide (27.5% w/v, 110 mL) and stirred vigourously for 30 minutes. Water (4 L) was added, the layers were separated and the aqueous layer was extracted with dichloromethane (3 x 1 L). The dichloromethane solutions were recombined with the original dichloromethane layer from the reaction mixture and this organic solution was dien washed with water (2 L) and brine (2 L), dried (MgSO4) and evaporated to afford a foam. !H NMR of this crude reaction mixture suggested a mixture of the desired aldol product (3 diastereoisomers, comprising 95% major diastereoisomer) and starting materials. The crude mixture was chromatographed on silica gel using a gradient elution comprising 15% ethyl acetate in dichloromethane initially (until die desired product began to elute) and rising to 50% ethyl acetate in dichloromethane to complete the elution of the desired product. Unreacted i ide and aldehyde were recovered from the early fractions, followed by a quantity of impure product and then the title compound (comprising 2 diastereoisomers, ratio 97.8:2.2 by NMR). [α]rj25
= +45° (c = 2.82, CHC13). [Found (El) M+ 613.2042. C31H3oF3N3O7 requires M+ 613.2036]; δH (CDCI3, only major diastercoisomer is recorded) 2.75 (IH, dd), 2.90 (IH, d, exchanges with D2O), 3.25 (IH, dd), 3.34 (3H, s), 3.80-4.00 (5H, m), 4.07 (IH, dd), 4.24 (2H, t), 4.45 (IH, m), 4.99 (IH, apparent t), 5.48 (IH, d), 6.85 (2H, d) and 6.95-7.40 (1 IH, m); δ> (CDCI3) = -74.7 (3F, t, HP 8.5, CF3). The minor diastereoisomer in the purified product was identified as die [3(25, 35), 45]-diastereo- isomer.
Procedure 10 Preparation of [3(25), 4S]-3-[3-[4-[2-[N-(2-Benzoxazolyl)-N- methylamino]ethoxy]phenyI]-2-(2,2,2-trifluoroethoxy)propaπoyl]-4- benzyloxazolidin-2-one by Dehydroxylation
Triediylsilane (120 mL, 0.75 mol) was added over 5 minutes to a stirred, ice cooled solution of [3(25, 3Λ), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N- medιylamino]ethoxy]phenyl]-3-hydroxy-2-(2^,2-trifluoroethoxy)propanoyl]-4- benzyloxazolidin-2-one (46.23 g, 7.5 x 10"2 mol) in trifluoroacetic acid (650 mL). The mixture was stirred at 0°C for 1 hour, then at room temperature for a further 60 hours. The bulk of die solvent and residual triediylsilane was removed by rotary evaporation, firstly at 40 mm Hg and finally at -5 mm Hg. The residue was dissolved in dichloromethane (800 mL) and water (800 mL), then stirred vigorously during the cautious addition of solid sodium bicarbonate (~29 g) (frothing !) until die pH of the aqueous layer was pH 7. The layers were separated and the aqueous layer was extracted widi dichloromediane (800 mL). The combined dichloromethane layers were washed with water (600 mL), dried (MgSO4) and evaporated. The residue was triturated wid hot hexane and the resulting solid collected by filtration. Recrystallisation from diethyl ether-hexane afforded the title compound, mp 107-109°C, a single diastereoisomer by l NMR spectroscopy. [α]rj25 = +38° (c = 1.51, CHCI3); [Found C, 62.1; H, 4.9; N, 7.2%; M+ (El) 597.2089.
C31H30N3O6F3 requires C, 62.3; H, 5.1; N, 7.0%; M+ 597.2087]; δH (CDCI3) 2.82 (IH, dd), 2.96 (IH, dd), 3.04 (IH, dd), 3.32 (IH, dd), 3.34 (3H, s), 3.70 (IH, m), 3.88 (IH, m), 3.94 (2H, t), 4.12 (IH, m), 4.18 (IH, m), 4.25 (2H, t), 4.57 (IH, m), 5.34 (IH, dd), 6.82 (2H, d) and 7.00-7.35 (1 IH, m); δF (CDCI3) = -74.8 (3F, t, ^ 8.6, CF3).
Procedure 11
Preparation of [3(2S), 4S]-3-[3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]- ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]-4-benzyloxazoIidin-2-one by
Diastereoisomer Separation
(5 -4-Benzyloxazolidin-2-one (0.291 g, 1.64 x 10"3 mol) was dissolved in dry THF (10 mL) and the resulting solution cooled to -70°C under argon. n-Butyl lithium (1.6M in hexane, 1.03 mL, 1.64 x 10-3 mol) was added and the mixture was stirred at -70°C for 10 minutes prior to the addition of a solution of (±)-3-[4-[2-[N-(2- benzoxazolyl)-N-memylamino]edιoxy]phenyl]-2-(2,2,2-trifluoroedιoxy)propanoyl chloride (prepared from 0.36 g of d e acid by Procedure 5, above) in dry THF (15 mL). The reaction was stirred and allowed to warm to room temperature overnight before being diluted widi water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined ethyl acetate layers were washed widi water (200 mL) and brine (200 mL), dried (MgSO4) and evaporated to give a brown gum. This was chromatographed on silica gel using a gradient of 35% to 50% ediyl acetate in hexane as eluent to afford firsdy the (R, 5 -diastereoisomer, followed by d e tide compound, a foam. This material was spectroscopically identical with that prepared by the aldol route (Procedure 10).
Procedure 12
(S)-MethyI 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2^,2- trifluoroethoxy)propanoate
A solution of sodium medioxide [prepared from sodium hydride (60% dispersion in mineral oil, 138 mg, 3.41 x 10-3 mol) dissolved in dry methanol (3.5 mL)] was added to an ice cooled and stirred suspension of [3(25), 45]-3-[3-[4-[2-[N-(2- benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]- 4-benzyloxazolidin-2-one (1.879 g, 3.1 x 10'3 mol) in dry methanol (100 mL). The mixture was stirred at 0°C for a total of 20 minutes, then the reaction was quenched by die addition of dilute aqueous hydrochloric acid (2.0M, 1.75 mL) and concentrated in vacua. The residue was suspended in water (100 mL), extracted with ethyl acetate
(3 x 200 mL) and the combined ediyl acetate solutions washed widi brine (500 mL), dried (MgSO4) and evaporated. The resulting gum was chromatographed on silica gel using 4% ethyl acetate in dichloromethane as eluent to afford die product as a clear gum. [a]O^ = 7° (c = 1.24, CHCI3); [Found (El) M+ 452.1561. C22H23N2O5F3 requires M+ 452.1559]; e.e. 100% (by HPLC); δH (CDCI3) 3.02 (2H, m), 3.34 (3H, s), 3.65 (IH, m), 3.72 (3H, s), 3.94 (2H, t), 4.00 (IH, m), 4.13 (IH, dd), 4.24 (2H, t), 6.80 (2H, d) and 6.96-7.40 (6H, m).
Procedure 13 (45)-4-Benzyl-3-[2-(2-methoxyethoxy)ethanoyl]oxazolidin-2-one
The tide compound was prepared from 2-(2-metiιoxyethoxy)etiιanoyl chloride by a method analogous to tiiat described in Procedure 8. Chromatography on silica gel using a gradient of 70-80% diethyl ether in hexane as eluent afforded the product as a gum. [αto25 = +54° (c = 2.70, CHC13); [Found (El) M+ 293.1263. C15H19NO5 requires M+ 293.1264]; δH (CDCI3) 2.81 (IH, dd), 3.33 (IH, dd), 3.41 (3H, s), 3.63 (2H, t), 3.78 (2H, t), 4.25 (2H, m), 4.70 (IH, m), 4.74 (IH, d), 4.76 (IH, d) and 7.10- 7.40 (5H, m).
Procedure 14
[3(2S, 3Λ), 4S]-3-[3-[4.[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-3- hydroxy-2-(2-methoxyethoxy)propanoyl]-4-benzyloxazolidin-2-one
The tide compound was prepared from (45)-4-benzyl-3-[2-(2- methoxyethoxy)ethanoyl]oxazolidin-2-one by a method analogous to that described in Procedure 9. The crude reaction mixture was chromatographed on silica gel using a gradient of 15-40% ethyl acetate in dichloromediane to afford die product as a gum (comprising 2 diastereoisomers, ratio >99:1 by !H NMR). [α]D 25 = +49° (c = 1.14, CHCI3). [Found (FAB, NOBA/Na) MH+ 590.2472. C32H35N3O8 requires MH+
590.2502]; δy (CDCI3, only major diastereoisomer is recorded) 2.71 (IH, dd), 3.25 (IH, dd), 3.31 (3H, s), 3.35 (3H, s), 3.56 (2H, m), 3.72 (2H, m), 3.78 (IH, d, exchanges with D2O), 3.85-4.00 (4H, m), 4.22 (2H, t), 4.31 (IH, m), 4.89 (IH, dd), 5.42 (IH, d), 6.83 (2H, d) and 6.95-7.40 (1 IH, m); The minor diastereoisomer in the purified product was identified as die [3(25, 35), 45]-diastereoisomer.
Procedure 15
[3(25), 4S]-3-[3-[4-[2-[N-(2-Benzoxazolyl)-N-methyiamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoyl]-4-benzyloxazolidin-2-one
[3(25, 3R), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-3- hydroxy-2-(2-medιoxyethoxy)propanoyl]-4-benzyloxazolidin-2-one (0.561 g) was reacted wid triediylsilane for 6.25 hrs in a manner similar to tiiat described for Procedure 10. The reaction mixture was diluted widi water (200 mL) and dichloromethane (200 mL) and solid sodium bicarbonate was added cautiously until die aqueous layer showed pH 6.5. The layers were separated, the aqueous layer was extracted widi dichloromediane (2 x 300 mL) and the combined dichloromediane solutions were washed widi brine (400 mL), dried (MgSO4) and evaporated. The residue was chromatographed on silica gel using 35% ethyl acetate in dichloromediane as eluent to afford d e tide compound, a gum, as a single diastereoisomer by *H NMR. [αJo25 = +45° (c = 1.39, CHCI3); [Found M+ (El) 573.2473. C32H35N3O7 requires M+ 573.2475]; δH (CDCI3) 2.76 (IH, dd), 2.94 (2H, m), 3.30 (3H, s), 3.33 (4H, m), 3.40-3.70 (4H, m), 3.93 (2H, t), 4.00 (IH, dd), 4.12 (IH, dd), 4.22 (2H, t), 4.52 (IH, m), 5.31 (IH, dd), 6.79 (2H, d) and 6.90-7.40 (l lH, m).
Procedure 16
(5)-Methyl 3-[4-[2-[N-(2-BenzoxazolyI)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoate
[3(25), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- medιoxyed oxy)propanoyl]-4-benzyloxazolidin-2-one was reacted widi sodium medioxide in a manner analogous to tiiat described in Procedure 12. The crude reaction mixture was chromatographed on silica gel using 20% isohexane in died yl edier as eluent to afford the title compound, a gum. [COD25 = -12° (c = 1.26, CHCI3); [Found (El) M+ 428.1974. C23H28N2O6 requires M+ 428.1948]; e.e. >99.8% (by HPLC); δH (CDCI3) 2.95 (2H, m), 3.29 (3H, s), 3.34 (3H, s), 3.35 (3H, m), 3.69 (4H, m), 3.93 (2H, t), 4.05 (IH, dd), 4.23 (2H, t) and 6.75-7.40 (8H, m).
DEMONSTRATION OF EFFICACY OF COMPOUNDS
Obese Mice, Oral Glucose Tolerance Test
C57M1/6 obese (ob/ob) mice were fed on powdered oxoid diet. After at least one week, the mice continued on a powdered oxoid diet or were fed powered oxoid diet containing die test compound. After 8 days on the supplemented diet all of die mice were fasted for 5 hours prior to receiving an oral load of glucose (3g/kg). Blood samples for glucose analysis were taken 0, 45, 90 and 135 minutes after glucose administration and d e results appear below as the percentage reduction in area under die blood glucose curve where test compound treated groups are compared with die control group. 8 mice were used for each treatment.
Table
% Reduction in
Level in diet area under blood imple (μmol. kg'1 of diet) glucose curve
1 0.3 24
2 0.3 24
Effects on packed red cell volume and heart weight:
These were determined after repeat oral administration of compound (once daily at a dose of 3 μmol kg body wt for 14 days, by gavage) to female Sprague- Dawley rats for 14 days. Changes shown are percentage changes from control. Statistical comparisons were made by Student t test for non-paired data; *p<0.05, ***p<0.001 versus controls. No effect no significant difference from control group. Results were obtained from 8 rats per treatment group.
Compound Heart weight Packed cell volume
Example (% increase) (% reduction)
1 No effect No effect
2 No effect No effect
Claims
1. A compound of formula (I) :
or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein R° represents 2-benzoxazolyl or 2-pyridyl and R* represents CH2OCH3 or CF3.
2. A compound according to claim 1, wherein R° represents 2-benzoxazolyl.
3. A compound according to claim 1, wherein R represents CF3
4. A compound according to claim 1 being:
5 -3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxy- edιoxy)propanoic acid;or
(5)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)propanoic acid; or a pharmaceutically acceptable salt diereof, and/or a pharmaceutically acceptable solvate diereof.
5. A compound of formula (I) according to claim 1, when present in admixture with less than 50% w/w of its racemic isomer.
6. A compound of formula (I) according to claim 1, when 90-100% optically pure.
7. A compound of formula (I) according to claim 1, in optically pure form.
8. A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
9. A method for die treatment and/or prophylaxis of hyperglycaemia or hyperlipidaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate diereof, to a hyperglycaemic human or non-human mammal in need thereof.
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9508468A BR9508468A (en) | 1994-07-29 | 1995-06-07 | Compound process for the preparation of the same pharmaceutical composition processes for the treatment and / or prophylaxis of hyperglycemia in a human or non-human mammal and for the treatment of hyperlipidemia hypertension cardiovascular disease some eating disorders the treatment and / or prophylaxis of kidney disease prevention revers o stabilization or retardation of microalbuminuria progression in a human or non-human mammal use of the compound and intermediate compound |
DZ950094A DZ1916A1 (en) | 1994-07-29 | 1995-07-26 | New compounds and pharmaceutical compositions containing them. |
IL11475995A IL114759A (en) | 1994-07-29 | 1995-07-27 | Benzoxazole derivatives and pharmaceutical compositions containing them |
MA23972A MA23632A1 (en) | 1994-07-29 | 1995-07-27 | PROCESS FOR THE PREPARATION OF NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
MX9700763A MX9700763A (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes. |
HU9700264A HUT76637A (en) | 1994-07-29 | 1995-07-28 | Bezoxazoles and pyridine derivatives, pharmaceutical compositions containing them, process for producing them and their use and the intermediates of the compounds |
EP95930436A EP0772605A1 (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes |
PL95318766A PL318766A1 (en) | 1994-07-29 | 1995-07-28 | Derivatives of benzoxazoles and pyridines useful in treating diabetes of type ii |
CN95195163A CN1158123A (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the type II diabetes |
CZ97254A CZ25497A3 (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives usable for treating type ii diabetes |
APAP/P/1997/000918A AP776A (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the type Ii diabetes. |
NZ292125A NZ292125A (en) | 1994-07-29 | 1995-07-28 | Benzoxazole and pyridine substituted phenyl carboxylic acid derivatives; medicaments |
AU33826/95A AU697545B2 (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the ty pe II diabetes |
JP8506194A JPH10503508A (en) | 1994-07-29 | 1995-07-28 | Benzoxazole and pyridine derivatives useful in the treatment of type II diabetes |
PCT/EP1995/003038 WO1996004260A1 (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes |
TR95/00916A TR199500916A2 (en) | 1994-07-29 | 1995-07-28 | New compounds to be used in the type. |
FI970357A FI970357A (en) | 1994-07-29 | 1997-01-28 | Benzoxazole and pyridine derivatives useful in the treatment of type II diabetes |
NO970373A NO307827B1 (en) | 1994-07-29 | 1997-01-28 | Benzoxazole and pyridine derivatives, their use and pharmaceutical preparations containing them |
BG101180A BG101180A (en) | 1994-07-29 | 1997-01-29 | Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes |
OA60957A OA10470A (en) | 1994-07-29 | 1997-01-29 | Benzoxazoles and pyridine derivates useful in the treatment of the type ii diabetes |
IL12552598A IL125525A0 (en) | 1994-07-29 | 1998-07-27 | Hydroxyalkylamine derivatives |
AU10061/99A AU1006199A (en) | 1994-07-29 | 1999-01-08 | Benzoxazoles and pyridine derivatives useful in the treatment of the Type II diabetes |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9415330.1 | 1994-07-29 | ||
GB9415330A GB9415330D0 (en) | 1994-07-29 | 1994-07-29 | Novel compounds |
GBGB9425599.9A GB9425599D0 (en) | 1994-12-19 | 1994-12-19 | Novel compounds |
GB9425599.9 | 1994-12-19 | ||
GBGB9509923.0A GB9509923D0 (en) | 1995-05-17 | 1995-05-17 | Novel compounds |
GB9509923.0 | 1995-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996004261A1 true WO1996004261A1 (en) | 1996-02-15 |
Family
ID=27267309
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/001323 WO1996004261A1 (en) | 1994-07-29 | 1995-06-07 | Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes |
PCT/EP1995/003038 WO1996004260A1 (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/003038 WO1996004260A1 (en) | 1994-07-29 | 1995-07-28 | Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0772605A1 (en) |
AP (1) | AP776A (en) |
BR (1) | BR9508468A (en) |
CA (1) | CA2196079A1 (en) |
CZ (1) | CZ25497A3 (en) |
DZ (1) | DZ1916A1 (en) |
FI (1) | FI970357A (en) |
HU (1) | HUT76637A (en) |
IL (3) | IL114759A (en) |
MA (1) | MA23632A1 (en) |
MX (1) | MX9700763A (en) |
NO (1) | NO307827B1 (en) |
OA (1) | OA10470A (en) |
PL (1) | PL318766A1 (en) |
SK (1) | SK12297A3 (en) |
WO (2) | WO1996004261A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997025042A1 (en) * | 1996-01-09 | 1997-07-17 | Smithkline Beecham P.L.C. | Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x |
WO2000023445A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023425A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023417A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023415A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023451A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023416A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063209A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063153A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063190A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063189A1 (en) * | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
US6214820B1 (en) | 1998-10-21 | 2001-04-10 | Novo Nordisk A/S | Compounds, their preparation and use |
US6248781B1 (en) | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
US6274608B1 (en) | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
US6300339B1 (en) | 1998-10-21 | 2001-10-09 | Novo Nordisk A/S | Compounds, their preparation and use |
US6365586B1 (en) | 1998-10-21 | 2002-04-02 | Novo Nordisk A/S | Compounds, their preparation and use |
US6369055B1 (en) | 1999-04-20 | 2002-04-09 | Novo Nordisk A/S | Compounds, their preparation and use |
US6468996B1 (en) | 1998-10-21 | 2002-10-22 | Novo Nordisk A/S | Substituted hetero-polycyclic compounds as PPARα and PPARγ activators |
US6555577B1 (en) | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
US6939853B2 (en) | 2001-12-29 | 2005-09-06 | Novo Nordisk A/S | Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
US6972294B1 (en) | 1999-04-20 | 2005-12-06 | Novo Nordisk, A/S | Compounds, their preparation and use |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
US7041837B2 (en) | 2001-07-26 | 2006-05-09 | Cadilla Healthcare Limited | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine |
BG65370B1 (en) * | 2000-01-19 | 2008-04-30 | Cadila Healthcare Ltd. | Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them |
US7414128B2 (en) | 1999-04-20 | 2008-08-19 | Dr. Reddy's Laboratories, Limited | Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate |
WO2012104869A1 (en) | 2011-01-31 | 2012-08-09 | Cadila Healthcare Limited | Treatment for lipodystrophy |
WO2015001573A1 (en) | 2013-07-05 | 2015-01-08 | Cadila Healthcare Limited | Synergistic compositions |
US9814697B2 (en) | 2013-04-22 | 2017-11-14 | Cadila Healthcare Limited | Composition for nonalcoholic fatty liver disease (NAFLD) |
US10098868B2 (en) | 2013-07-25 | 2018-10-16 | Cadila Healthcare Limited | Formula comprising a hypolipidemic agent |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
US10435363B2 (en) | 2013-05-30 | 2019-10-08 | Cadila Healthcare Limited | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
US11433050B2 (en) | 2016-12-09 | 2022-09-06 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0916651B1 (en) * | 1996-04-04 | 2003-10-15 | Sankyo Company, Limited | Phenylalkylcarboxylic acid derivatives |
US6090839A (en) * | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
KR20010030881A (en) | 1997-10-02 | 2001-04-16 | 가와무라 요시부미 | Amidocarboxylic acid derivatives |
AU1198699A (en) | 1997-10-27 | 1999-04-23 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them |
HUP0101110A3 (en) | 1997-10-27 | 2002-06-28 | Reddys Lab Ltd Dr | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO1999019313A1 (en) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US6265401B1 (en) | 1997-10-27 | 2001-07-24 | Reddy-Cheminor, Inc. | Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
KR100517644B1 (en) * | 1997-10-27 | 2005-09-28 | 닥터 레디스 레보러터리즈 리미티드 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
PL341795A1 (en) * | 1998-05-27 | 2001-05-07 | Reddy Research Foundation | Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds |
PL346661A1 (en) | 1998-09-17 | 2002-02-25 | Bristol Myers Squibb Co | Method for treating diabetes employing an ap2 inhibitor and combination |
CN1323300A (en) | 1998-10-29 | 2001-11-21 | 雷迪研究基金会 | An improved process for the preparation of new antidiabetic agents |
US6531596B1 (en) | 1998-10-29 | 2003-03-11 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of new antidiabetic agents |
SK15092001A3 (en) * | 1999-04-28 | 2002-05-09 | Dr. Reddy's Research Foundation | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
WO2001016120A1 (en) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
CN1396904A (en) * | 2000-01-28 | 2003-02-12 | 诺沃挪第克公司 | Novel compound, their preparation and use |
US6509374B2 (en) | 2000-04-17 | 2003-01-21 | Novo Nordisk A/S | Compounds, their preparation and use |
PT1280784E (en) * | 2000-05-12 | 2007-09-03 | Ortho Mcneil Pharm Inc | De |
AU2001259747A1 (en) | 2000-05-12 | 2001-11-26 | Ortho-Mcneil Pharmaceutical, Inc. | Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment |
US6908908B2 (en) | 2000-05-12 | 2005-06-21 | Ortho-Mcneil Pharmaceutical, Inc. | Biologically active 4H-benzo [1,4] oxazin-3-ones |
WO2001087861A2 (en) * | 2000-05-12 | 2001-11-22 | Ortho-Mcneil Pharmaceutical, Inc. | Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators |
US6869967B2 (en) | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
US7220877B2 (en) | 2001-10-17 | 2007-05-22 | Novo Nordisk A/S | Compounds, their preparation and use |
US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
US6653334B1 (en) | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
JPWO2008139879A1 (en) * | 2007-04-26 | 2010-07-29 | ファルマフロンティア株式会社 | G protein-coupled receptor inhibitor and pharmaceutical |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019702A1 (en) * | 1990-06-14 | 1991-12-26 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
WO1994001420A1 (en) * | 1992-07-03 | 1994-01-20 | Smithkline Beecham Plc | Heterocyclic compounds as pharmaceutical |
-
1995
- 1995-06-07 BR BR9508468A patent/BR9508468A/en unknown
- 1995-06-07 WO PCT/GB1995/001323 patent/WO1996004261A1/en active Search and Examination
- 1995-07-26 DZ DZ950094A patent/DZ1916A1/en active
- 1995-07-27 IL IL11475995A patent/IL114759A/en unknown
- 1995-07-27 IL IL12552595A patent/IL125525A/en unknown
- 1995-07-27 MA MA23972A patent/MA23632A1/en unknown
- 1995-07-28 SK SK122-97A patent/SK12297A3/en unknown
- 1995-07-28 WO PCT/EP1995/003038 patent/WO1996004260A1/en not_active Application Discontinuation
- 1995-07-28 EP EP95930436A patent/EP0772605A1/en not_active Withdrawn
- 1995-07-28 CZ CZ97254A patent/CZ25497A3/en unknown
- 1995-07-28 AP APAP/P/1997/000918A patent/AP776A/en active
- 1995-07-28 HU HU9700264A patent/HUT76637A/en unknown
- 1995-07-28 MX MX9700763A patent/MX9700763A/en unknown
- 1995-07-28 PL PL95318766A patent/PL318766A1/en unknown
- 1995-07-28 CA CA002196079A patent/CA2196079A1/en not_active Abandoned
-
1997
- 1997-01-28 FI FI970357A patent/FI970357A/en unknown
- 1997-01-28 NO NO970373A patent/NO307827B1/en not_active IP Right Cessation
- 1997-01-29 OA OA60957A patent/OA10470A/en unknown
-
1998
- 1998-07-27 IL IL12552598A patent/IL125525A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019702A1 (en) * | 1990-06-14 | 1991-12-26 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
WO1994001420A1 (en) * | 1992-07-03 | 1994-01-20 | Smithkline Beecham Plc | Heterocyclic compounds as pharmaceutical |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166049A (en) * | 1996-01-09 | 2000-12-26 | Smithkline Beecham P.L.C. | Use of an antagonist of PPARα and PPARγ for the treatment of syndrome X |
WO1997025042A1 (en) * | 1996-01-09 | 1997-07-17 | Smithkline Beecham P.L.C. | Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x |
US6703401B2 (en) | 1998-10-21 | 2004-03-09 | Novo Nordisk A/S | Compounds, their preparation and use |
US6525086B2 (en) | 1998-10-21 | 2003-02-25 | Novo Nordisk A/S | Compounds, their preparation and use |
WO2000023415A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023451A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023416A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023445A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
US6723731B2 (en) | 1998-10-21 | 2004-04-20 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
US6683111B2 (en) | 1998-10-21 | 2004-01-27 | Novo Nordisk A/S | Compounds, their preparation and use |
US6602901B2 (en) | 1998-10-21 | 2003-08-05 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
WO2000023425A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
US6214820B1 (en) | 1998-10-21 | 2001-04-10 | Novo Nordisk A/S | Compounds, their preparation and use |
US6248781B1 (en) | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
WO2000023417A1 (en) * | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
US6300339B1 (en) | 1998-10-21 | 2001-10-09 | Novo Nordisk A/S | Compounds, their preparation and use |
US6353018B1 (en) | 1998-10-21 | 2002-03-05 | Novo Nordisk A/S | Compounds, their preparation and use |
US6365586B1 (en) | 1998-10-21 | 2002-04-02 | Novo Nordisk A/S | Compounds, their preparation and use |
US6468996B1 (en) | 1998-10-21 | 2002-10-22 | Novo Nordisk A/S | Substituted hetero-polycyclic compounds as PPARα and PPARγ activators |
US6407127B2 (en) | 1998-10-21 | 2002-06-18 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
WO2000063189A1 (en) * | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
US6369055B1 (en) | 1999-04-20 | 2002-04-09 | Novo Nordisk A/S | Compounds, their preparation and use |
US6274608B1 (en) | 1999-04-20 | 2001-08-14 | Novo Nordisk A/S | Compounds, their preparation and use |
US6972294B1 (en) | 1999-04-20 | 2005-12-06 | Novo Nordisk, A/S | Compounds, their preparation and use |
US7414128B2 (en) | 1999-04-20 | 2008-08-19 | Dr. Reddy's Laboratories, Limited | Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate |
WO2000063190A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063153A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000063209A1 (en) * | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
BG65370B1 (en) * | 2000-01-19 | 2008-04-30 | Cadila Healthcare Ltd. | Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
US7202213B2 (en) | 2000-01-28 | 2007-04-10 | Novo Nordisk A/S | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders |
US6555577B1 (en) | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
US6867218B2 (en) | 2000-01-28 | 2005-03-15 | Novo Nordisk A/S | Compounds, their preparation and use |
US8558009B2 (en) | 2001-07-26 | 2013-10-15 | Cadila Healthcare Limited | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
US7323491B2 (en) | 2001-07-26 | 2008-01-29 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
US7041837B2 (en) | 2001-07-26 | 2006-05-09 | Cadilla Healthcare Limited | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine |
US8110598B2 (en) | 2001-07-26 | 2012-02-07 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
US6939853B2 (en) | 2001-12-29 | 2005-09-06 | Novo Nordisk A/S | Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
US7015345B2 (en) | 2002-02-21 | 2006-03-21 | Asahi Kasei Pharma Corporation | Propionic acid derivatives |
US9783495B2 (en) | 2011-01-31 | 2017-10-10 | Cadila Healthcare Limited | Treatment for lipodystrophy |
WO2012104869A1 (en) | 2011-01-31 | 2012-08-09 | Cadila Healthcare Limited | Treatment for lipodystrophy |
EP3009136A1 (en) | 2011-01-31 | 2016-04-20 | Cadila Healthcare Limited | Treatment for lipodystrophy |
US10017470B2 (en) | 2011-01-31 | 2018-07-10 | Cadila Healthcare Limited | Treatment for lipodystrophy |
US9814697B2 (en) | 2013-04-22 | 2017-11-14 | Cadila Healthcare Limited | Composition for nonalcoholic fatty liver disease (NAFLD) |
US10435363B2 (en) | 2013-05-30 | 2019-10-08 | Cadila Healthcare Limited | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
US9656954B2 (en) | 2013-07-05 | 2017-05-23 | Cadila Healthcare Limited | Synergistic compositions |
US9957230B2 (en) | 2013-07-05 | 2018-05-01 | Cadila Healthcare Limited | Synergistic compositions |
EP3120845A1 (en) | 2013-07-05 | 2017-01-25 | Cadila Healthcare Limited | Synergistic compositions |
WO2015001573A1 (en) | 2013-07-05 | 2015-01-08 | Cadila Healthcare Limited | Synergistic compositions |
US10315993B2 (en) | 2013-07-05 | 2019-06-11 | Cadila Healthcare Limited | Synergistic compositions |
US10098868B2 (en) | 2013-07-25 | 2018-10-16 | Cadila Healthcare Limited | Formula comprising a hypolipidemic agent |
US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
US11433050B2 (en) | 2016-12-09 | 2022-09-06 | Cadila Healthcare Ltd. | Treatment for primary biliary cholangitis |
US11872209B2 (en) | 2016-12-09 | 2024-01-16 | Zydus Lifesciences Limited | Treatment for primary biliary cholangitis |
Also Published As
Publication number | Publication date |
---|---|
EP0772605A1 (en) | 1997-05-14 |
OA10470A (en) | 2002-04-08 |
IL125525A0 (en) | 1999-03-12 |
FI970357A (en) | 1997-03-26 |
DZ1916A1 (en) | 2002-02-17 |
CZ25497A3 (en) | 1997-09-17 |
BR9508468A (en) | 1997-11-25 |
NO970373D0 (en) | 1997-01-28 |
HUT76637A (en) | 1997-10-28 |
SK12297A3 (en) | 1997-08-06 |
NO307827B1 (en) | 2000-06-05 |
NO970373L (en) | 1997-03-18 |
PL318766A1 (en) | 1997-07-07 |
WO1996004260A1 (en) | 1996-02-15 |
IL114759A0 (en) | 1995-12-31 |
IL125525A (en) | 2000-02-29 |
MX9700763A (en) | 1997-05-31 |
FI970357A0 (en) | 1997-01-28 |
CA2196079A1 (en) | 1996-02-15 |
IL114759A (en) | 1999-10-28 |
MA23632A1 (en) | 1996-04-01 |
AP776A (en) | 1999-10-28 |
AP9700918A0 (en) | 1997-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP776A (en) | Benzoxazoles and pyridine derivatives useful in the treatment of the type Ii diabetes. | |
US6166049A (en) | Use of an antagonist of PPARα and PPARγ for the treatment of syndrome X | |
US5869495A (en) | Heterocyclic compounds as pharmaceutical | |
US5132317A (en) | Compounds | |
US5478851A (en) | Dioxothiazolidine compounds | |
EP0320628B1 (en) | Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase | |
US5032602A (en) | Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones | |
WO1994013650A1 (en) | Heterocyclic derivatives and their use in pharmaceuticals | |
WO1995017394A1 (en) | Heterocyclic derivatives and their use in pharmaceuticals | |
GB2305665A (en) | Selective ß3 agonists for the treatment of diabetes aand obesity | |
US5478850A (en) | Thiazolidinedione derivatives | |
WO1995003288A1 (en) | Heteroaromatic derivatives and their use in therapeutics | |
EP0299620A1 (en) | Thiazolidinedione derivatives | |
AU697545B2 (en) | Benzoxazoles and pyridine derivatives useful in the treatment of the ty pe II diabetes | |
US5589492A (en) | Heterocyclic compounds and their use in the treatment of Type-II diabetes | |
WO1994029302A1 (en) | Heterocyclic derivatives and their use in pharmaceuticals | |
AU4381900A (en) | Use of an antagonist of PPAR-alpha and PPAR-gamma for the treatment of SyndromeX |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): MG US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 776499 Date of ref document: 19970428 Kind code of ref document: A Format of ref document f/p: F |